Angiotech Pharmaceuticals

ANP-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about ANP-T

Signal
Opinion
Expert
TOP PICK
TOP PICK
September 28, 2004
Has real earnings that are identifiable. Could see them making $0.35US this year and growing to $0.80US next year. Market share is back again in spite of the recall troubles they experienced. Looking to diversify the stent further away from the heart.
Show full opinionHide full opinion
Has real earnings that are identifiable. Could see them making $0.35US this year and growing to $0.80US next year. Market share is back again in spite of the recall troubles they experienced. Looking to diversify the stent further away from the heart.
DON'T BUY
DON'T BUY
August 27, 2004
There should be some recovery and show that they have good products coming out. Do not rush to own the stocks.
Show full opinionHide full opinion
There should be some recovery and show that they have good products coming out. Do not rush to own the stocks.
DON'T BUY
DON'T BUY
August 24, 2004
To tell when a stock has bottomed, you need to see more trading at the low level indicating that the sell off is over. Stock is on a negative trend.
Show full opinionHide full opinion
To tell when a stock has bottomed, you need to see more trading at the low level indicating that the sell off is over. Stock is on a negative trend.
BUY
BUY
August 23, 2004
Had some troubles along with Boston Scientific with stent recalls. FDA is allowing them to keep stents three months longer which created a bit of a rally. Reasonable value at this price.
Show full opinionHide full opinion
Had some troubles along with Boston Scientific with stent recalls. FDA is allowing them to keep stents three months longer which created a bit of a rally. Reasonable value at this price.
TOP PICK
TOP PICK
August 17, 2004
Feels they handled their recent problems extremely well. Have quite a good product mix going forward.
Show full opinionHide full opinion
Feels they handled their recent problems extremely well. Have quite a good product mix going forward.
DON'T BUY
DON'T BUY
August 12, 2004
A difficult one. A clever Company and an important one. Very deeply based on the stent business.
Show full opinionHide full opinion
A difficult one. A clever Company and an important one. Very deeply based on the stent business.
WAIT
WAIT
July 28, 2004
Got knocked down because of a short term recall on Boston Scientific stents. A short-term problem. Wait and see.
Show full opinionHide full opinion
Got knocked down because of a short term recall on Boston Scientific stents. A short-term problem. Wait and see.
DON'T BUY
DON'T BUY
July 23, 2004
Boston Scientific just did a recall on 85,000 stents. Nothing wrong with the Angiotech product, but their partner is having a problem, so at this point it's a gamble.
Show full opinionHide full opinion
Boston Scientific just did a recall on 85,000 stents. Nothing wrong with the Angiotech product, but their partner is having a problem, so at this point it's a gamble.
VAGUE
VAGUE
July 19, 2004
The market has been hurting them because they have not branched out into other areas. The recall of Boston Scientific's stent has also hurt.
Show full opinionHide full opinion
The market has been hurting them because they have not branched out into other areas. The recall of Boston Scientific's stent has also hurt.
BUY
BUY
July 14, 2004
Built a big base from 2000 into 2003 and then took off but at $40 the stock started to weaken. In the minor downtrend. Support will probably come at the $22/23 so you could start buying.
Show full opinionHide full opinion
Built a big base from 2000 into 2003 and then took off but at $40 the stock started to weaken. In the minor downtrend. Support will probably come at the $22/23 so you could start buying.
DON'T BUY
DON'T BUY
June 25, 2004
Prefers businesses with as much visibility as possible so they can get their minds around. Has done an amazing job. Brutally competitive market. Prefers companies with more diversification.
Show full opinionHide full opinion
Prefers businesses with as much visibility as possible so they can get their minds around. Has done an amazing job. Brutally competitive market. Prefers companies with more diversification.
TOP PICK
TOP PICK
June 23, 2004
Price has dropped and looks at this as an opportunity. Competition is not strong. Lots of cash. Well-positioned.
Show full opinionHide full opinion
Price has dropped and looks at this as an opportunity. Competition is not strong. Lots of cash. Well-positioned.
VAGUE
VAGUE
June 23, 2004
The big question is, Will their stent covering continue to hold a major share of the market.
Show full opinionHide full opinion
The big question is, Will their stent covering continue to hold a major share of the market.
DON'T BUY
DON'T BUY
June 18, 2004
Having Boston Scientific involved and Johnson and Johnson having problems with their stent, is already priced into the stock.
Show full opinionHide full opinion
Having Boston Scientific involved and Johnson and Johnson having problems with their stent, is already priced into the stock.
HOLD
HOLD
June 16, 2004
Doesnt know if it's a good point of entry. A single product company. Story is well known.
Show full opinionHide full opinion
Doesnt know if it's a good point of entry. A single product company. Story is well known.
Showing 61 to 75 of 140 entries